MARC details
| 000 -LEADER |
|---|
| fixed length control field |
08727cam a22004694i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
16020881 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20190512132402.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
091211s2010 njuab b 001 0 eng |
| 010 ## - LIBRARY OF CONGRESS CONTROL NUMBER |
|---|
| LC control number |
2009052133 |
| 015 ## - NATIONAL BIBLIOGRAPHY NUMBER |
|---|
| National bibliography number |
GBB049446 |
| Source |
bnb |
| 016 7# - NATIONAL BIBLIOGRAPHIC AGENCY CONTROL NUMBER |
|---|
| Record control number |
101521082 |
| Source |
DNLM |
| 016 7# - NATIONAL BIBLIOGRAPHIC AGENCY CONTROL NUMBER |
|---|
| Record control number |
015529388 |
| Source |
Uk |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780470307786 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
0470307781 |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
(OCoLC)ocn489623096 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
DNLM/DLC |
| Transcribing agency |
DLC |
| Modifying agency |
YDX |
| -- |
NLM |
| -- |
YDXCP |
| -- |
UKM |
| -- |
CDX |
| -- |
BWX |
| -- |
DLC |
| Description conventions |
rda |
| 042 ## - AUTHENTICATION CODE |
|---|
| Authentication code |
pcc |
| 050 00 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
QP552.G16 |
| Item number |
G627 2010 |
| 060 00 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
|---|
| Classification number |
2010 I-880 |
| 060 10 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
|---|
| Classification number |
QV 38 |
| Item number |
G725 2010 |
| 082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
612.015756 |
| Edition number |
22 |
| Item number |
G |
| 245 00 - TITLE STATEMENT |
|---|
| Title |
GPCR molecular pharmacology and drug targeting : |
| Remainder of title |
shifting paradigms and new directions / |
| Statement of responsibility, etc |
edited by Annette Gilchrist. |
| 264 #4 - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Date of publication, distribution, etc |
c2010. |
| 264 #1 - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Place of publication, distribution, etc |
Hoboken, N.J. : |
| Name of publisher, distributor, etc |
Wiley, |
| Date of publication, distribution, etc |
[2010] |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xxi, 520 pages, [16] pages of plates : |
| Other physical details |
ill. (some color) ; |
| Dimensions |
25 cm |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes bibliographical references and index. |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Preface. Contributors. 1. The Evolution of Receptors: From On-Off Switches to Microprocessors ( Terry Kenakin ) . 1.1. Introduction. 1.2. The Receptor as an On-Off Switch. 1.3. Historical Background and Classical Receptor Theory. 1.4. The Operational Model of Drug Action. 1.5. Receptor Antagonism. 1.6. Specific Models of GPCRs (7TM Receptors). 1.7. The Receptor as Microprocessor: Ternary Complex Models. 1.8. Receptors as Basic Drug Recognition Units. 1.9. Receptor Structure. 1.10. Future Considerations. References. 2. The Evolving Pharmacology of GPCRs 27 ( Lauren T. May, Nicholas D. Holliday, and Stephen J. Hill ) . 2.1. Agonists, Neutral Antagonists, and Inverse Agonists. 2.2. LDTRS/Protean Agonism. 2.3. Molecular Mechanisms of GPCR Ligand Binding. 2.4. Two GPCR Ligands Binding at Once-Concept of Allosterism. 2.5. GPCR Dimerization. 2.6. Future Perspectives. Acknowledgments. References. 3. The Emergence of Allosteric Modulators for G Protein-Coupled Receptors ( Karen J. Gregory, Celine Valant, John Simms, Patrick M. Sexton, and Arthur Christopoulos ) . 3.1. Introduction. 3.2. Foundations of Allosteric Receptor Theory. 3.3. Models for Understanding the Effects of Allosteric Modulators. 3.4. Types of Allosteric Modulators and Their Properties. 3.5. Detection and Quantification of Allosteric Interactions. 3.6. Some Examples of GPCR Allosteric Modulators. 3.7. Concluding Remarks. References. 4. Receptor-Mediated G Protein Activation: How, How Many, and Where? ( Ingrid Gsandtner, Christian W. Gruber, and Michael Freissmuth ) . 4.1. The Mechanical Problem-Three Different Solutions. 4.2. Receptor Monomers-Dimers-Oligomers: One Size Fits All? 4.3. Corrals, Fences, Rafts-Are There Privileged Places for GPCR Activation? Acknowledgments. References. 5. Molecular Pharmacology of Frizzleds-with Implications for Possible Therapy ( Gunnar Schulte ) . 5.1. Introduction. 5.2. Frizzleds as WNT Receptors. 5.3. Frizzled Signaling 120. 5.4. Frizzleds-Physiology and Possible Therapy. Acknowledgments. References. 6. Secretin Receptor Dimerization: A Possible Functionally Important Paradigm for Family B G Protein-Coupled Receptors ( Kaleeckal G. Harikumar, Maoqing Dong, and Laurence J. Miller ) . 6.1. Methodological Approaches to GPCR Oligomerization. 6.2. Structural Themes for GPCR Oligomerization. 6.3. Functional Effects of GPCR Oligomerization. 6.4. Secretin Receptor Oligomerization. References. 7. Past and Future Strategies for GPCR Deorphanization ( Angelique Levoye, Nathalie Clement, Elodie Tenconi and Ralf Jockers ) . 7.1. Introduction. 7.2. Current Strategies to Identify the Ligand and Function of Orphan 7TM Proteins. 7.3. Functional Assays for Deorphanization. 7.4. Future Directions and New Concepts. 7.5. Controversial Issues. Acknowledgments. References. 8. High-Throughput GPCR Screening Technologies and the Emerging Importance of the Cell Phenotype ( Terry Reisine and Richard M. Eglen ) . 8.1. Introduction. 8.2. How Are GPCR Drugs Discovered? 8.3. GPCR Dependence on G Proteins. 8.4. Technologies for GPCR Compound Screening and Drug Discovery. 8.5. Importance of Target Cells in GPCR HTS Assays. 8.6. Summary. References. 9. Are "Traditional" Biochemical Techniques Out of Fashion in the New Era of GPCR Pharmacology? ( Maria Teresa Dell'anno and Maria Rosa Mazzoni ) . 9.1. Overview. 9.2. Receptor Binding Assays. 9.3. Methods for Measurement of cAMP. 9.4. Conclusions. References. 10. Fluorescence and Resonance Energy Transfer Shine New Light on GPCR Function ( Carsten Hoffmann and Moritz Bunemann ) . 10.1. Overview. 10.2. Introduction. 10.3. Labeling GPCRs with Fluorescent Tags. 10.4. Detection of Fluorescence and Bioluminescence. 10.5. Fluorescence-Based Assays to Study Receptor Localization, Trafficking and Receptor Function. 10.6. Resonance Energy Transfer, a Tool to Get New Insights into GPCR Function. 10.7. Analysis of Steady-State Protein-Protein Interaction by Means of RET. 10.8. Kinetic Analysis of Protein-Protein Interactions by Means of FRET. 10.9. Detection of Receptor Function by Fluorescence Resonance Energy. References. 11. Integration of Label-Free Detection Methods in GPCR Drug Discovery ( Oliver Nayler, Magdalena Birker-Robaczewska, and John Gatfield ) . 11.1. Overview. 11.2. Introduction. 11.3. Label-Free Technologies-Past and Present. 11.4. Discussion. Acknowledgments. References. 12. Screening for Allosteric Modulators of G Protein-Coupled Receptors ( Christopher Langmead ) . 12.1. Introduction. 12.2. The Allosteric Ternary Complex Model, Radioligand Binding, and Affinity. 12.3. Beyond Affinity-Functional Assays, Efficacy, and Allosteric Agonism. 12.4. Allosteric Modulator Titration Curves. 12.5. The Impact of Functional Assay Format on Allosteric Modulator Screening. 12.6. Taking Advantage of Structural Understanding of Allosteric Binding Sites. 12.7. Summary and Future Directions. References. 13. Ultra-High-Throughput Screening Assays for GPCRs ( Priya Kunapuli ) . 13.1. Introduction. 13.2. Assay Types for GPCRs in uHTS. 13.3. Summary. Acknowledgments. References. 14. New Techniques to Express and Crystallize G Protein-Coupled Receptors ( James C. Errey and Fiona H. Marshall ) . 14.1. Introduction. 14.2. Key Problems Limiting Production of 3D GPCR Structures. 14.3. History of GPCR Structures. 14.4. The Search for Other GPCR Structures. 14.5. Protein Purification and Solubilization. 14.6. In Cubo Crystallization. 14.7. Engineering Receptor Stability. 14.8. Structures of the a2AR. 14.9. The Adenosine A2a Receptor. 14.10. Conclusions and Future Developments. Acknowledgments. References. 15. Structure and Modeling of GPCRs: Implications for Drug Discovery ( Kimberly A. Reynolds, Vsevolod Katritch, and Ruben Abagyan ) . 15.1. Introduction. 15.2. High-Resolution GPCR Modeling. 15.3. Constructing and Evaluating Homology Models of Other Receptor Types. 15.4. Modeling GPCR Functional Features-Analysis of Activation and Signaling. 15.5. Beyond Class A: Modeling of Other GPCR Families. 15.6. Summary and Conclusions. Acknowledgments. References. 16. X-Ray Structure Developments for GPCR Drug Targets ( Michael Sabio and Sidney W. Topiol ) . 16.1. Overview. 16.2. Introduction. 16.3. Class A GPCRs. 16.4. Class C GPCRs. 16.5. Conclusions. References. 17. Pharmacological Chaperones: Potential for the Treatment of Hereditary Diseases Caused by Mutations in G Protein-Coupled Receptors ( Kenneth J. Valenzano, Elfrida R. Benjamin,Patricia Rene, and Michel Bouvier ) . 17.1. Overview. 17.2. Introduction. 17.3. NDI and the V2R. 17.4. RP and the Rhodopsin Receptor. 17.5. IHH and the Gonadotropin-Releasing Hormone Receptor. 17.6. Other Human Diseases Caused by Inactivating Mutations in GPCRs. 17.7. Considerations for the Therapeutic Use of Pharmacological Chaperones. 17.8. Concluding Remarks. Acknowledgments. References. Index. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc |
G protein-coupled receptors (GPCRs), are a large protein family of transmembrane receptors that sense molecules outside the cell and activate inside signal transduction pathways and, ultimately, cellular responses. GPCRs are involved in many diseases, but are also the target of around half of all modern medicinal drugs. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
G proteins. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Drug targeting. |
| 650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Receptors, G-Protein-Coupled |
| General subdivision |
physiology. |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Drug Delivery Systems. |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Molecular Structure. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Gilchrist, Annette, |
| Relator term |
editor. |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Materials specified |
Abstract |
| Uniform Resource Identifier |
<a href="http://repository.fue.edu.eg/xmlui/handle/123456789/1740">http://repository.fue.edu.eg/xmlui/handle/123456789/1740</a> |
| 906 ## - LOCAL DATA ELEMENT F, LDF (RLIN) |
|---|
| a |
7 |
| b |
cbc |
| c |
orignew |
| d |
1 |
| e |
ecip |
| f |
20 |
| g |
y-gencatlg |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Books |